Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

Summary

This study was planned to compare deferasirox and desferrioxamine in terms of mean serum ferritin levels in patients of β-thalassemia major having Iron overload. Choosing an effective iron chelator is crucial to increasing iron chelation therapy compliance. Not much local data exists in Pakistan comparing the effectiveness of deferasirox (DFX) and desferrioxamine (DFO), so, this study would be helpful in providing baseline data and formulating new protocols for iron chelation therapy, in which DFX may be a useful oral alternative to parenteral DFO.

Timeline

Start

2023-01-01

Primary completion

2023-09-30

Completion

2023-09-30

Drugs

Indications